FMO5 and cardiac hypertrophy: GIP further decreases cardiac hypertrophy and interstitial fibrosis in diabetic db/db mice and decreases NADPH oxidase-driven superoxide production and expression of markers indicative of fibrosis (Ctgf) and heart hypertrophy (β-Mhc and Tgf-β2) in isolated mouse cardiomyocytes [861].